Search - tctmd.com

Displaying 41 - 60 of 127

Sort: Relevancy | Date

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Presenter: Dean J. Kereiakes, Pieter C. Smits

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Tullio Palmerini

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

News Conference News TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

Presentation TCT 2015

TCT 65: Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Postapproval Study (PE-Plus PAS)

Presenter: Sigmund Silber, Philip M. Urban, David E. Kandzari

October 13, 2015

Presentation TCT 2015

TCT 6: Five-Year Optical Coherence Tomography of Patients With ST-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents (the RE-EXAMINATION Study)

Presenter: Eric Boersma, Richard Smalling, Josep Gomez Lara

October 13, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Presenter: Marije L?wik

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

Advertisement

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

TCT 65: Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Postapproval Study (PE-Plus PAS)

TCT 6: Five-Year Optical Coherence Tomography of Patients With ST-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents (the RE-EXAMINATION Study)

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

DAPT Study Subanalysis Focuses on EES Subgroup

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content